Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 68 | 0.820 |
Why?
|
| Bronchoscopy | 2 | 2020 | 35 | 0.750 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 360 | 0.740 |
Why?
|
| Lymphangitis | 1 | 2021 | 3 | 0.730 |
Why?
|
| Carcinoma | 1 | 2021 | 74 | 0.680 |
Why?
|
| Bronchial Neoplasms | 1 | 2020 | 4 | 0.660 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 151 | 0.660 |
Why?
|
| Lipoma | 1 | 2020 | 11 | 0.650 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 300 | 0.590 |
Why?
|
| Lung | 4 | 2022 | 382 | 0.400 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2022 | 43 | 0.340 |
Why?
|
| Orthomyxoviridae Infections | 2 | 2022 | 40 | 0.340 |
Why?
|
| Smoke | 2 | 2021 | 37 | 0.340 |
Why?
|
| Influenza A virus | 2 | 2022 | 37 | 0.330 |
Why?
|
| Male | 11 | 2022 | 13943 | 0.330 |
Why?
|
| Humans | 19 | 2022 | 28896 | 0.330 |
Why?
|
| Metrorrhagia | 1 | 2010 | 1 | 0.320 |
Why?
|
| Uterine Cervical Diseases | 1 | 2010 | 6 | 0.320 |
Why?
|
| Histoplasmosis | 1 | 2010 | 10 | 0.320 |
Why?
|
| Cigarette Smoking | 2 | 2022 | 84 | 0.320 |
Why?
|
| Influenza, Human | 2 | 2022 | 93 | 0.320 |
Why?
|
| Hospitalization | 2 | 2021 | 201 | 0.320 |
Why?
|
| Adult | 7 | 2022 | 8035 | 0.290 |
Why?
|
| Middle Aged | 9 | 2022 | 7416 | 0.290 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2007 | 2 | 0.270 |
Why?
|
| HIV Infections | 1 | 2010 | 165 | 0.270 |
Why?
|
| Tobacco Products | 2 | 2021 | 209 | 0.270 |
Why?
|
| Fibrous Dysplasia, Polyostotic | 1 | 2006 | 2 | 0.250 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2006 | 4 | 0.250 |
Why?
|
| Tuberculosis | 1 | 2006 | 25 | 0.240 |
Why?
|
| Cystic Fibrosis | 1 | 2006 | 34 | 0.240 |
Why?
|
| Female | 8 | 2021 | 15646 | 0.240 |
Why?
|
| Fatal Outcome | 2 | 2021 | 67 | 0.190 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 379 | 0.190 |
Why?
|
| Dexamethasone | 1 | 2022 | 63 | 0.190 |
Why?
|
| Aged | 3 | 2021 | 5599 | 0.190 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2021 | 15 | 0.180 |
Why?
|
| Dyspnea | 1 | 2021 | 25 | 0.180 |
Why?
|
| Lung Injury | 1 | 2022 | 33 | 0.180 |
Why?
|
| Communicable Diseases | 1 | 2022 | 20 | 0.180 |
Why?
|
| Lymphatic Metastasis | 1 | 2021 | 126 | 0.180 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 190 | 0.170 |
Why?
|
| Pneumonia | 1 | 2022 | 89 | 0.170 |
Why?
|
| Oxygen | 1 | 2022 | 237 | 0.170 |
Why?
|
| Goblet Cells | 1 | 2021 | 15 | 0.170 |
Why?
|
| Receptor, Notch3 | 1 | 2021 | 15 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 481 | 0.170 |
Why?
|
| Academic Medical Centers | 1 | 2021 | 76 | 0.170 |
Why?
|
| Bronchi | 1 | 2021 | 38 | 0.170 |
Why?
|
| Interferon-gamma | 1 | 2021 | 108 | 0.170 |
Why?
|
| Medicare | 1 | 2021 | 126 | 0.170 |
Why?
|
| Pinocytosis | 1 | 2020 | 17 | 0.160 |
Why?
|
| Macrophages, Alveolar | 1 | 2020 | 36 | 0.160 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2020 | 7 | 0.160 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 210 | 0.160 |
Why?
|
| Leukocytes | 1 | 2020 | 72 | 0.160 |
Why?
|
| Phagocytosis | 1 | 2020 | 80 | 0.160 |
Why?
|
| Interferons | 1 | 2020 | 70 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 409 | 0.150 |
Why?
|
| Hypertension | 1 | 2022 | 309 | 0.150 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 285 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2021 | 464 | 0.150 |
Why?
|
| Antigens, Bacterial | 1 | 2020 | 165 | 0.150 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 415 | 0.140 |
Why?
|
| Bacterial Toxins | 2 | 2020 | 273 | 0.140 |
Why?
|
| Cell Differentiation | 1 | 2021 | 427 | 0.140 |
Why?
|
| Retrospective Studies | 2 | 2022 | 2635 | 0.140 |
Why?
|
| Oklahoma | 1 | 2020 | 1053 | 0.130 |
Why?
|
| United States | 2 | 2021 | 2226 | 0.120 |
Why?
|
| Pulmonary Edema | 1 | 2015 | 9 | 0.120 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 2065 | 0.110 |
Why?
|
| Treatment Outcome | 1 | 2021 | 2426 | 0.110 |
Why?
|
| Tomography, Emission-Computed | 1 | 2007 | 6 | 0.070 |
Why?
|
| False Negative Reactions | 1 | 2007 | 24 | 0.070 |
Why?
|
| Animals | 5 | 2022 | 10703 | 0.070 |
Why?
|
| Time Factors | 2 | 2021 | 1613 | 0.060 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 100 | 0.060 |
Why?
|
| Mycobacterium avium Complex | 1 | 2006 | 3 | 0.060 |
Why?
|
| Mycobacterium chelonae | 1 | 2006 | 4 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 2 | 2022 | 1659 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2006 | 32 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 524 | 0.060 |
Why?
|
| Restraint, Physical | 1 | 2003 | 14 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2003 | 33 | 0.050 |
Why?
|
| Chemical Warfare Agents | 1 | 2003 | 4 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2003 | 50 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2003 | 93 | 0.050 |
Why?
|
| Critical Care | 1 | 2003 | 49 | 0.050 |
Why?
|
| Boidae | 1 | 2002 | 2 | 0.050 |
Why?
|
| Salmonella enterica | 1 | 2002 | 9 | 0.050 |
Why?
|
| Platelet Transfusion | 1 | 2002 | 29 | 0.050 |
Why?
|
| Renin-Angiotensin System | 1 | 2022 | 18 | 0.050 |
Why?
|
| Salmonella Infections | 1 | 2002 | 18 | 0.050 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 9 | 0.050 |
Why?
|
| Chemical Warfare | 1 | 2002 | 3 | 0.050 |
Why?
|
| Biological Warfare | 1 | 2002 | 6 | 0.050 |
Why?
|
| Terrorism | 1 | 2002 | 10 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 32 | 0.050 |
Why?
|
| Warfare | 1 | 2002 | 10 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2022 | 56 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2003 | 245 | 0.050 |
Why?
|
| Interferon-beta | 1 | 2022 | 40 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 536 | 0.040 |
Why?
|
| Tobacco | 1 | 2022 | 87 | 0.040 |
Why?
|
| Mice | 2 | 2022 | 4809 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2021 | 28 | 0.040 |
Why?
|
| Receptors, Peptide | 1 | 2020 | 20 | 0.040 |
Why?
|
| RAW 264.7 Cells | 1 | 2020 | 21 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 92 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 2020 | 32 | 0.040 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2020 | 15 | 0.040 |
Why?
|
| Necrosis | 1 | 2020 | 85 | 0.040 |
Why?
|
| Spores, Bacterial | 1 | 2020 | 49 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2020 | 114 | 0.040 |
Why?
|
| Smokers | 1 | 2021 | 129 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 134 | 0.040 |
Why?
|
| Respiratory Mucosa | 1 | 2020 | 68 | 0.040 |
Why?
|
| Transcriptome | 1 | 2021 | 232 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 739 | 0.040 |
Why?
|
| Bacillus anthracis | 1 | 2020 | 153 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 612 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2021 | 1022 | 0.040 |
Why?
|
| Cell Line | 1 | 2020 | 700 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 668 | 0.030 |
Why?
|
| Apoptosis | 1 | 2020 | 780 | 0.030 |
Why?
|
| Biomarkers | 1 | 2020 | 777 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 1508 | 0.030 |
Why?
|
| Airway Obstruction | 1 | 2015 | 20 | 0.030 |
Why?
|
| Disease Management | 1 | 2015 | 91 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2021 | 1469 | 0.030 |
Why?
|
| Young Adult | 1 | 2020 | 2839 | 0.020 |
Why?
|
| Adolescent | 1 | 2020 | 3198 | 0.020 |
Why?
|
| Safety | 1 | 2003 | 32 | 0.010 |
Why?
|
| Poisoning | 1 | 2003 | 2 | 0.010 |
Why?
|
| Serotyping | 1 | 2002 | 10 | 0.010 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2002 | 4 | 0.010 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2002 | 9 | 0.010 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2002 | 45 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 2002 | 56 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2002 | 113 | 0.010 |
Why?
|
| Child | 1 | 2003 | 2292 | 0.010 |
Why?
|